HTK preservative solution is associated with increased biliary complications among patients receiving DCD liver transplants: A single center experience

Annals of Transplantation

Volumn 18, Issue 1, 2013, Pages 69-75

  Gulsen, Murat T ^a   Girotra, Mohit ^a   Cengiz Seval, Guldane ^a   Price, Jennifer ^a   Singh, Vikesh K ^a   Segev, Dorry L ^a,b,c   Cameron, Andrew M ^a,c   Gurakar, Ahmet ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biliary complications; DCD; HTK; Liver transplantation; Preservative; UW

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HTK SOLUTION; UNIVERSITY OF WISCONSIN SOLUTION;

ADULT; ANASTOMOTIC STRICTURE; ARTICLE; BILIARY LEAK; BILIARY TRACT DISEASE; CLINICAL ARTICLE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; FOLLOW UP; HEART DEATH; HEPATIC ARTERY THROMBOSIS; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; ISCHEMIA; LIVER TRANSPLANTATION; MALE; NON ANASTOMOTIC STRICTURE; RETROSPECTIVE STUDY;

ADENOSINE; ADULT; ALLOPURINOL; ANASTOMOSIS, SURGICAL; ANASTOMOTIC LEAK; BILIARY TRACT; CONSTRICTION, PATHOLOGIC; FEMALE; GLUCOSE; GLUTATHIONE; HEPATIC ARTERY; HUMANS; INSULIN; LIVER TRANSPLANTATION; MALE; MANNITOL; MIDDLE AGED; ORGAN PRESERVATION SOLUTIONS; POSTOPERATIVE COMPLICATIONS; POTASSIUM CHLORIDE; PROCAINE; RAFFINOSE; REOPERATION; RETROSPECTIVE STUDIES; THROMBOSIS; TISSUE DONORS;

EID: 84877081719     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.883831     Document Type: Article

References (18)

1. Lee KW, Simpkins CE, Montgomery RA et al: Factors affecting graft survival after liver transplantation from donation after cardiac death donors. Transplantation, 2006; 82: 1683-88
2. Stewart ZA, Cameron AM, Singer AL et al: Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death. Am J Transplant, 2009;9: 286-93
3. Esquivel CO: Liver transplantation: where we are and where we are heading. Transplant Proc, 2010; 42: 610-12
4. Feng L, Zhao N, Yao X et al: Histidine-tryptophan-ketoglutarate solution vs. University of Wisconsin solution for liver transplantation: a systematic review. Liver Transpl, 2007; 13: 1125-36
5. Maheshwari A, Maley W, Li Z, Thuluvath PJ: Biliary complications and outcomes of liver transplantation from donors after cardiac death. Liver Transpl, 2007; 13: 1645-53
6. Skaro AI, Jay CL, Baker TB et al: The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery, 2009; 146: 543-52; discussion 552-53
7. Grewal HP, Willingham DL, Nguyen J et al: Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience. Liver Transpl, 2009; 15: 1028-35
8. Sharma S, Gurakar A, Jabbour N: Biliary strictures following liver transplantation: past, present and preventive strategies. Liver Transpl, 2008; 14: 759-69
9. Erhard J, Lange R, Scherer R et al: Comparison of histidine-tryptophan-ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantation. A prospective, randomized study. Transpl Int, 1994; 7: 177-81
10. Rayya F, Harms J, Martin AP et al: Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution in adult liver transplantation. Transplant Proc, 2008; 40: 891-94
11. Tullius SG, Filatenkow A, Horch D et al: Accumulation of crystal deposits in abdominal organs following perfusion with defrosted University of Wisconsin solutions. Am J Transplant, 2002; 2: 627-30
12. Canelo R, Hakim NS, Ringe B: Experience with hystidine tryptophan ketoglutarate versus University Wisconsin preservation solutions in transplantation. Int Surg, 2003; 88: 145-51
13. Mangus RS, Fridell JA, Vianna RM et al: Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution in extended criteria liver donors. Liver Transpl, 2008; 14: 365-73
14. Pareja E, Cortes M, Navarro R et al: Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis. Transplant Proc, 2010; 42: 2970-72
15. Moray G, Sevmis S, Karakayali FY et al: Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin in living-donor liver transplantation. Transplant Proc, 2006; 38: 3572-75
16. Chan EY, Olson LC, Kisthard JA et al: Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transpl, 2008; 14: 604-10
17. de Vera ME, Lopez-Solis R, Dvorchik I et al: Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant, 2009; 9: 773-81
18. Dolinska B, Budzinski G, Caban A et al: Prolactin (PRL) reduces the release of transaminases from the isolated pig liver. Ann Transplant, 2011; 16(2): 98-102